Pediatric Transplants

Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan

Article metrics

Abstract

Langerhans cell histiocytosis (LCH) that is refractory to conventional chemotherapy has a poor outcome. Hematopoietic stem cell transplanta tion (SCT) is a promising approach for refractory LCH because of its immunomodulatory effect. In this study, the outcomes of children with refractory LCH undergoing SCT in Japan were analyzed. Between November 1995 and March 2007, 15 children younger than 15 years (9 males, 6 females) with refractory LCH underwent SCT. The patients’ median age at diagnosis was 8 months (range, 28 days to 28 months), and all had failed conventional chemotherapy. The median age at SCT was 23 months (range, 13–178 months). Nine had risk organ involvement at diagnosis, including liver (n=6), spleen (n=5), lung (n=5), and/or hematopoietic system (n=4). For SCT, a myeloablative regimen was used for 10 patients, and a reduced-intensity conditioning regimen (RIC) was used for five. The donor source varied among the patients, but allogeneic cord blood was primarily used (n=10). Subsequently, 11 of 15 patients have survived with no evidence of disease, with a 10-year overall survival (OS) rate (median±standard error) of 73.3±11.4%. The 10-year OS rate of nine patients with risk organ involvement at diagnosis was 55.6±16.6%, whereas six without risk organ involvement have all survived with no evidence of disease (P=0.07). These results indicate that SCT is promising as a salvage approach for children with refractory LCH.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1

References

  1. 1

    McClain KL, Natkunam Y, Swerdlow SH . Atypical cellular disorders. Hematology Am Soc Hematol Educ Program 2004, 283–296.

  2. 2

    Stephan JL . Histiocytoses. Eur J Pediatr 1995; 154: 600–609.

  3. 3

    Henter JI, Tondini C, Pritchard J . Histiocyte disorders. Crit Rev Oncol Hematol 2004; 50: 157–174.

  4. 4

    Minkov M, Grois N, Heitger A, Pötschger U, Westermeier T, Gadner H, DAL-HX Study Group. Response to initial treatment of multisystem Langerhans cell histiocytosis: an important prognostic indicator. Med Pediatr Oncol 2002; 39: 581–585.

  5. 5

    Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A et al. A randomized trial of treatment for multisystem Langerhans’ cell histiocytosis. J Pediatr 2001; 138: 728–734.

  6. 6

    Gadner H, Grois N, Pötschger U, Minkov M, Aricò M, Braier J et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood 2008; 111: 2556–2562.

  7. 7

    A multicentre retrospective survey of Langerhans’ cell histiocytosis: 348 cases observed between 1983 and 1993. The French Langerhans’ Cell Histiocytosis Study Group. Arch Dis Child 1996; 75: 17–24.

  8. 8

    Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M et al. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer 2006; 107: 613–619.

  9. 9

    Bernard F, Thomas C, Bertrand Y, Munzer M, Landman Parker J, Ouache M et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer 2005; 41: 2682–2689.

  10. 10

    Steiner M, Matthes-Martin S, Attarbaschi A, Minkov M, Grois N, Unger E et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant 2005; 36: 215–225.

  11. 11

    Caselli D, Aricò M, EBMT Paediatric Working Party. The role of BMT in childhood histiocytoses. Bone Marrow Transplant 2008; 41: S8–S13.

  12. 12

    Kaplan EL, Meier P . Nonparametric estimation for incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

  13. 13

    Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS March 31, 2003 (http://ctep.cancer.gov), Publish Date: December 12, 2003.

  14. 14

    Schag CC, Heinrich RL, Ganz PA . Karnofsky performance status revisited: reliability, validity, and guidelines. J Clin Oncol 1984; 2: 187–193.

  15. 15

    Ringden O, Ahstrom L, Lonnqvist B, Båryd I, Svedmyr E, Gahrton G . Allogeneic bone marrow transplantation in a patient with chemotherapy-resistant progressive histiocytosis X. N Engl J Med 1987; 316: 733–735.

  16. 16

    Kinugawa N, Imashuku S, Hirota Y, Yamada K, Yamamoto A, Akazai A et al. Hematopoietic stem cell transplantation (HSCT) for Langerhans cell histiocytosis (LCH) in Japan. Bone Marrow Transplant 1999; 24: 935–938.

  17. 17

    Steiner M, Matthes-Martin S, Attarbaschi A, Lawitschka A, Minkov M, Mittheisz E et al. Importance of allogeneic T-cells for disease control after stem cell transplantation for high-risk Langerhans cell histiocytosis. Haematologica 2007; 92: e3–e4.

Download references

Acknowledgements

We thank the following for providing information on their patients: Hama A (Nagoya University), Matsubayashi T (Seirei Hamamatsu General Hospital), Hayakawa A (Kobe University), Osugi Y (Osaka General Medical Center), Ida K (The University of Tokyo), Koga Y (Kyushu University), Ueyama J (Tottori University), Yoshida M (Asahikawa Medical College), Yamamoto S (Showa University Fujigaoka Hospital), and all JSPH members. We also thank Takahashi H (University of Tsukuba) for helpful discussion regarding the statistical analysis. This work was supported by a Grant for Research on Measures for Intractable Diseases from the Ministry of Health, Labor and Welfare, Japan.

Author information

Correspondence to K Kudo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and Permissions

About this article

Keywords

  • Langerhans cell histiocytosis
  • refractory
  • stem cell transplantation
  • reduced intensity conditioning

Further reading